Thyroid hormones (TH) are actively taken up into target cells via TH-transmembrane transporters (THTT). Their activity and expression patterns define a layer of endocrine regulation that is poorly understood. Therefore, THTT are potential targets for interfering agents (endocrine disruptors) as well as for pharmacological interventions. Inactivating mutations have been identified as the underlying cause of heritable diseases (monocarboxylate transporter 8-associated Allan-HerndonDudley syndrome) and might also define a class of subclinical TH insensitivity. As a basic tool to solve questions regarding THTT substrate specificity, activation or inactivation by compounds and functional changes from mutations, uptake assays with radiolabeled tracers are standard. Due to the need for radioactive isotopes, this technique is limited to screening of labelled substrates and disadvantageous regarding handling, setup, and regulatory issues. To overcome these hurdles, we developed an uptake assay protocol using nonradioactive ligands. In brief, uptake of nonradioactive iodine-containing substrate molecules was monitored via Sandell-Kolthoff reaction. The novel assay was designed to the common microtiter plate layout. As a prove-of-principle, we measured TH uptake by monocarboxylate transporter 8-transfected MDCK1 cells. Titrations with bromosulphthalein as an example for inhibitor screening setups and a side-by-side comparison with the radioactive method prove this assay to be reliable, sensitive, and convenient. Furthermore, the method was applicable on primary murine astrocytes, which enables high-throughput screening studies on in vitro model systems with physiological transporter regulation. Due to its design, it is applicable for high-throughput screening of modulatory compounds, but it is also a safe, inexpensive and an easily accessible method for functional testing of THTT in basic science. (Endocrinology 156: 2739 -2745, 2015) 
T hyroid hormone (TH) action is regulated on many levels of hierarchy, starting from biosynthesis, secretion, and distribution, followed by intracellular activation and inactivation via iodothyronine deiodinases. For a long time, TH were thought to enter their target cells via simple diffusion. Nowadays, it is well known that as charged amino acid derivatives, they are actively transported across cellular membranes by various transporter molecules, eg, monocarboxylate transporter (MCT)8, MCT10, OATP1C1, and L-type amino acid transporters (LAT) (1) . Being more or less ligand specific, they exhibit an individually regulated gene expression pattern, tissue-specific expression, and substrate affinity, creating a dominating layer of cell type-specific regulation of TH action (2/15) . Defects of these transporters, as it was extensively investigated for the MCT8, have consequences for the organism in embryogenesis and later on, leading to a severe neuromuscular phenotype, the Allan-Herndon-Dudley syndrome (3, 4) . Animal models uncovered a species-specific, dynamic mechanism of compensation and complementation between these THtransmembrane transporters (THTT) (3) (4) (5) . Pharmacological substances were shown to be able to interfere with THTT function. Tyrosine kinase inhibitors, eg, Sunitinib, can interrupt TH-transport via MCT8 and were characterized as non-competitive inhibitors (6) . Conversely, compounds that might scavenge or reactivate specific transporters are potential treatment options in THTT-related pathologies. Studies on TH-function need a specific set of methods. Uptake of TH or derivatives is investigated via classical radioactive tracer uptake assays, which rely due to the direct detection of substrate in-or efflux, on the availability of suitable, radioactivelabeled tracer molecules (7) . Alternative substrates may be detected by competition assays of tracer transport. A more sophisticated and flexible method is detection of transport via LC-MS/MS analysis. It is superior with regard to substrate flexibility and allows quantitative and qualitative codetection of multiple TH forms and even their breakdown products. Its only disadvantage is the limited high-throughput option, but even more severe, the costs for instrumentation, maintenance, assay standardizations, and the demand for technical expertise. Overall, if available, this is probably the gold-standard method for these studies (7) .
Inspired by previous work (8, 9) , we have developed a nonradioactive microtiter plate-based assay, using the classical iodide-quantification via the Sandell-Kolthoff (SK) reaction (10) and adapting it to high-throughput screening (HTS) requirements. The method provides a fast, simplified, highly accessible, and immensely cost-effective way to perform systematic studies on THTT function. It is well suited for broad studies to identify pharmacological or natural/environmental compounds that might interfere with transporter function.
The assay permitted the monitoring of T 3 uptake by MCT8-overexpressing MDCK cells. Uptake assays with various substrate compounds confirmed the published specificity of MCT8 and therefore qualified the assay to test a variety of iodinated compounds as potential ligands. Its applicability for HTS of modulating compounds and/or inhibitors was verified by an IC 50 determination for the known inhibitor bromosulphthalein (BSP), confirming the results of a back-to-back experiment with the transport assay using a radioactive tracer. Furthermore, we were able to apply the method on primary astrocytes successfully, thereby expanding its use to a further physiological cell culture model.
Materials and Methods

Materials
Chemicals used in the assay were analytical grade and obtained from Sigma-Aldrich AG or Carl Roth GmbH. Polysterole 96-well flat bottom microtiter plates used as assay plates were purchased from Techno Plastic products AG. Iodothyronines were acquired from Formula GmbH or Sigma-Aldrich AG.
Cell culture
MDCK1 cells were either stably transfected with an MCT8 expression vector or with empty vector (pcDNA3/MOCK), as described before (6) . MDCK1 cell populations were cultured in DMEM:F-12 (L-glutamine, 15mM HEPES) (Thermo Fisher) supplemented with antibiotics (1% penicillin [10 U/L] ϩ streptomycin [10 g/L]) and 10% fetal calf serum (Biochrom). Cell cultures were kept in a cell incubator at 37°C with 5% CO 2 saturation.
Isolation und cultivation of primary astrocytes
Cerebellae from 1-3 day old Mct8-deficient pups and wildtype littermates were dissected under a stereo microscope. Dissociated cells were plated in culture medium (DMEM with 4.5-g/L glucose and 10% FCS) and grown at 37°C and 5% CO 2 . Astrocytes were kept for 3 weeks with regular medium changes. Flasks were shaken at 500 rpm and 37°C overnight to remove microglia. For nonradioactive uptake assays, 50 ϫ 10 3 wild-type or Mct8-deficient astrocytes per well were seeded on a poly-Llysine-coated microtiter plate. Uptake assays were performed within a week.
For radioactive uptake assays, astrocytes were directly seeded in triplicates per genotype on poly-L-lysine coated 12-well microtiter plates and grown for up to 3 weeks until confluency and further treated as described above.
Preparation of assay plates
After reaching 80%-100% cell confluency, cells were trypsinized for 10 minutes at 37°C. Then, the suspension was distributed into 96-well microtiter plates with 50 ϫ 10 3 cells/ well. Subsequently, the plates were cultivated for 24 hours to obtain a single cell layer and a sufficiently high degree of adherence.
Substrate uptake assay
Assay plates with MDCK1 cells were washed once with 200 L/well PBS and kept at 37°C using a heating plate. Every well received 80 L uptake buffer (HEPES; pH 7.4 supplemented with 125mM NaCl, 1.3mM calcium-chloride, 1.2mM magnesium-chloride, 5mM potassium-chloride, and 5.6mM D-glucose). Subsequently, test compounds (eg, BSP) or substrates were prepared as 10-fold stock in uptake buffer. Adding 20 L substance stock to the assay plate started the uptake experiment.
After the given periods of time, the uptake reaction was stopped by removing the buffer, quickly followed by 2 washing steps with PBS supplemented with 0.1% BSA and ice-cold double-distilled water.
Oxidative digest
To release the iodide from substrates tested, an oxidative digest was initiated by adding 50 L ammonium persulfate (APS) (0.68M final concentration [f.c.]) to each well (11) . The plate was sealed tightly with a self-adhesive tape and incubated at 90°C for 1 hour. After incubation, the tape was removed and supernatant was diluted with double-distilled water in a new 96-well microtiter plate (usually 1:4 ratio) in a total volume of 50 L/well.
Iodine quantification
For the next pipetting steps, we used electronic pipetting devices (Proline 1200 L; Biohit) with multichannel serial dispensing option to allow a synchronized start of the detection reaction. The detection of iodide moieties was prepared by adding 50 L ceric solution (25mM (NH 4 ) 4 Ce(SO 4 ) 4 and 0.5M H 2 SO 4 ) to each well. The iodide-catalyzed destaining reaction was initiated by adding 50 L arsenous solution (25mM NaAsO 2 , 0.5M H 2 SO 4 , and 0.2M NaCl). Immediately, the changes in absorption at 415 nm were recorded (25°C, Microplate Reader 3550 with incubator; Bio-Rad). For relative quantification, the difference of absorption at the starting point (1 min) and after 21 minutes was equalized to cellular iodine content reflecting the relative uptake of the iodinated test compounds.
Uptake of radioactively labeled T 3
Inhibition studies were performed in MCT8-expressing MDCK1 cells that were exposed to 10nM [
125 I]T 3 (PerkinElmer Life Sciences) and increasing concentrations of BSP for 5 minutes.
Cell culture, [ 125 I]T 3 purification and radioactivity measurements were performed as described previously (7).
Statistical methods
Unless indicated otherwise, the mean Ϯ SEM is shown. For graphs and the calculation of IC 50 values, we used the 4-parameter logistic fitting nonlinear regression model offered by GraphPad Prism software version 6.0. Assay parameters were assessed and calculated as described by Iversen et al (12) .
Results
Validation of the nonradioactive substrate detection assay by T 3 uptake with MCT8-overexpressing MDCK1 cells
As a proof-of-principle experiment, MCT8-MDCK1 cells were incubated with T 3 (f.c. 5M), the preferred substrate for MCT8 for increasing periods of time up to 30 minutes. MOCK-transfected MDCK1 cells served as control. T 3 uptake by MCT8-transfected MDCK1 cells was clearly detectable and increased steadily over time ( Figure  1 ). Although the relative T 3 uptake increased in MCT8-transfected cells over time, the signal measured with pcDNA3-transfected MDCK1 control cells (MOCK) remained significantly lower after 30 minutes. This background signal probably results from MCT8-independent transport or unspecific binding over time, which cannot be excluded. Therefore, proper controls are needed for each experimental setting.
Assessment of the substrate spectrum of MCT8 in vitro
Unlike the radioactive assay, which requires tracer-labeled iodothyronines, the nonradioactive uptake assay does not require labeled substrates. Therefore, this nonradioactive approach enables parallel testing of a broad range of iodinated substrates, we evaluated a selection of iodothyronines (f.c. of 10M or 5M) in uptake buffer with the stably transfected cell lines. After 15 minutes of incubation with MCT8-MDCK1 cells, relative uptake was quantified as described before. MOCK-transfected cells served as controls to identify MCT8-independent uptake of the different compounds (Figure 2A ). The graphs clearly depict the specific substrate spectrum for MCT8. This experiment verified the data known in literature (6) . As illustrated (Figure 3A) , the high uptake signal of T 3 nicely corresponded to the known selectivity of MCT8. Some less intense transport of T 4 and 3,3Ј-T 2 was noted, whereas the other iodothyronines were not taken up as judged by less than a 2-fold signal-to-background ratio (fold change). Because the iodothyronines tested differ in the number of iodine moieties, direct comparisons between each of the iodothyronines are limited.
Inhibition of MCT8-mediated T 3 transport
To further validate the assay, the IC 50 for a known inhibitor of TH transporters, ie, BSP, was determined. A time-course experiment with fixed BSP concentration (100M) and a concentration-response experiment with increasing concentrations of BSP resulted in decreased T 3 uptake by MCT8-MDCK1 cells (Figure 2, B and C) .
Comparison of the nonradioactive vs radioactive substrate uptake assay
To confirm the inhibitory effect of BSP and the ability of the novel assay to generate uptake data for fast inhibitor screenings, we determined the IC 50 in parallel to a second method, ie, the radioactive uptake assay (Figure 2, C and  D) . The IC 50 values of BSP experimentally determined press.endocrine.org/journal/endowith both assay methods were nearly identical with 75M and 84M, respectively.
T 3 uptake in primary astrocytes
Primary astrocytes from Mct8-deficient mice were used to verify whether the nonradioactive approach is appropriate to be used with this more physiological cell system. Indeed, Mct8-mediated T 3 uptake was detected in wild-type astrocytes compared with those derived from knockout animals. Results from the nonradioactive approach in microtiter format ( Figure 3A) were almost similar to the orthogonal radioactive approach in 12-well formate ( Figure 3B ).
Evaluation of assay performance
The technical performance of the assay was further evaluated with selected statistic parameters for assay per- ). Wild-type astrocytes showed a well-detectable uptake of T 3 in both assay variants, the nonradioactive assay (n ϭ 3) (A) compared with the radioactive assay setup (n ϭ 3) (B). Uptake in the knockout-derived cells was much weaker and difference was interpreted as MCT8-specific transport. formance (Table 1) , which were calculated according to Zhang et al (13) and Iversen et al (12) . Taking these parameters, we can estimate the intra-and interassay variance. For this step, we chose the T 3 uptake assay setup with and without the presence of the TH transport inhibitor BSP and the IC 50 determination of BSP. The fold change describes the interplate variation in an assay setup. Taking the ratio of the max and min signal obtained in the assay, the fold change was clearly above 2.0, which underlines the low interplate variation. The second assay parameter was the Z'-factor, which evaluates the signal separation of positive and negative control samples in the assay setup. For our assay, we calculated Z'-factors. They had been in an optimal range between 0.5 and below 1.0 for assays with an increasing substrate concentration, ie, the T 3 uptake assay and above 0.5 for assays with a constant substrate concentration, ie, the dose-response curve with constant [T 3 ]. The remaining assay parameter is the coefficient of variance (CV) in percentage that describes the intraplate variation. Our assay showed a constant CV below 10% thereby underscoring a good intraassay performance (data not shown). In summary, these statistical parameters emphasize that this novel method enables a high-quality assay performance with robust reliability.
Discussion
Cellular import and export of TH is an expanding research topic. Therefore, reliable and innovative methods are needed to empower scientists to speed up their approaches on modulator screening and functional testing of the increasing number of THTT molecules identified (4, 13) . Especially the fact that some pharmaceuticals in clinical use were identified as interfering compounds of THTT action, leading to adverse effects in patients treated with such compounds, indicates the urgent need to systematically assess such possible interferences for the patients' safety (6) .
So far, TH transport was not yet included as a potential target function in any program or initiative of risk assessment for natural or anthropogenic compounds despite the fact that specific and selective modulators for these transporters are of great interest. Some of the THTT are expressed specifically in a subset of cells, therefore representing promising pharmacological targets for tissuespecific regulation of TH transport and action.
All of these topics need a fast, reliable, and simplified type of assay for effective and broad adaptation by the scientific community. The classical radioactive method to quantify TH uptake is limited due to expensive radiolabeled substrates, handling and safety issues, and complicated by strict regulations of waste management. Moreover, labeled TH analogues are not available for all potential TH substrates and their metabolites of interest. LC-MS/MS circumvents these issues, but is also limited with regard to HTS options and accessibility (14) . Recently, we published a nonradioactive method to measure enzyme activity of the iodothyronine deiodinase type 1 by a relatively simple read-out, ie, the quantification of catalytically active iodide in the cerium arsenite redox reaction originally described by Sandell and Kolthoff (10) .
Encouraged by our experiences, we now developed a HTS-adaptable nonradioactive uptake assay based upon the same signal read-out. MDCK1 cells expressing the THTT MCT8 served as a model system to optimize assay conditions and setup, to evaluate assay performance (Tab. 1) and to conduct prove-of-principle experiments ( Figures  1 and 2) . To further test the issue of applicability, we conducted experiments on primary astrocytes, isolated from mice lacking the Mct8-transporter in comparison with their wild-type littermates (Figure 3) . Here, we succeeded in monitoring Mct8-dependent T 3 transport into primary cells with comparable results with the radioactive approach.
Although the experimental flow of this new assay is almost identical to the radioactive version, we evaded the necessity of radioactive tracers, minimized the experimental size to a 96-well microtiter format, and streamlined the whole procedure for the use of multichannel pipets as a preparation for HTS experiments. To characterize the assay performance in terms of intra-/interassay variance, sensitivity and reproducibility, 2 specific assay parameters, ie, the fold change (ratio of max. signal and min. signal), the Z'-factor and the CV (data not shown) were calculated (10, 11) . Assay performances are shown for the T 3 uptake assay in presence of inhibitory BSP and the IC 50 [BSP] assay.
doi: 10.1210/en.2015-1016 press.endocrine.org/journal/endoA digestion step (APS digest, as described for urine samples) (11) was included to degrade the molecular structure of the substrate and to liberate iodide for catalytic detection by the SK reaction. This reaction enables the application of the assay principles to virtually all iodine-containing low molecular weight compounds, because APS destroys these molecules by oxidation liberating iodide, which acts as catalyst in the SK detection reaction. The substrate concentration on the cells was adjusted to 5M or 10M in almost all experiments, because the assay is limited by the detection limit of the SK reaction.
This assay allows to detect and follow the uptake of the preferred MCT8 substrate T 3 over time ( Figure 2) and to assess the inhibitory potential of BSP in a dose-dependent manner, thereby allowing IC 50 determinations ( Figure  3C ). These data were repeatedly confirmed by parallel experiments using the classical, radioactive approach (Figure 3D) . Moreover, our assay enables to monitor the uptake of various iodothyronines into MCT8-expressing cells, which are hardly available as radio-tracer molecules ( Figure 3A) . Although this experimental setup would require LC-MS/MS technique or a competitive experimental setting in the radioactive assay variant (due to limited availability of labeled tracers of, eg, T 2 ), our setup allows the direct detection of these substrates and thus assists in evaluating the substrate spectrum of the transporter, well in agreement with the current literature (7, 15, 16) .
The major limitation of the nonradioactive assay is its lower sensitivity as compared with the isotope-based methods, necessitating relatively high substrate concentration. This drawback is compensated for by the low priced test compounds as compared with the radiolabeled tracers. Titration experiments with T 4 and T 3 (Supplemental Table 1 ) corroborated that substrate concentration might be decreased to approximately 1M, but the relative percentage of transported substrate needed for proper detection rises in parallel (Supplemental Figure 2) . Thus, depending upon cell type as well as type and free concentration of substrate itself, longer incubation times need to be evaluated for each individual setup in order to obtain robust signal intensity.
An additional issue for these types of experiments is the distinct surface binding character of some of these compounds, eg, T 4 was found to produce higher background signal than the other TH under incubation conditions, cell density, and pH chosen (Supplemental Figure 1) . Therefore, we reduced its concentration from 10M to 5M. Each substrate should be carefully observed for its background binding characteristics, because it may strongly interfere with the THTT-dependent uptake signal. In contrast, we detected no comparable increase in background signal with T 3 , T 2 , and T 1 moieties.
Further tests are also needed to fully explore the potential applications of this assay and its suitability for HTS experiments. In addition, the experimental distinction between binding of ligands to the cellular surface vs THTTmediated uptake requires careful attention and additional technical adaptations, but this aspect holds also true for the alternative methods. However, the direct use of iodinecontaining ligands as potential THTT substrates avoids the complexities of the competitive approach of the radioisotope methods, thus reducing the number of possible interfering steps.
In summary, the nonradioactive TH uptake assay is a straightforward, cost-effective, and convenient method for TH transporter studies, especially for HTS approaches, even with primary cells (Supplemental Figure 3) . It also opens the field of transport studies to scientists with limited access to LC-MS/MS technology or isotope lab facilities and enables the use of primary cells which allows HTS studies using in vitro model systems with physiological transporter regulation.
Because it is build up on the fundament of the SK reaction and uses the same detection setup as the recently published nonradioactive deiodinase activity assay (8), establishing one of these methods will automatically provide an easy access to the other method, and vice versa.
